Multiple-biomarker Approach for Individualized Treatment of Heart Failure with Preserved Ejection Fraction
NCT ID: NCT06785506
Last Updated: 2025-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2022-11-25
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Moreover several secondary objectives will be investigated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Prospective Observational Study Evaluating the Management of Heart Failure
NCT05180370
Characterization of Heart Failure With Preserved Ejection Fraction
NCT03197350
Renal-based Optimization of QUADruple Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
NCT06273280
Predictors of Poor Prognosis in HFpEF
NCT06844032
Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
NCT05479669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart failure patients visiting the outpatient clinic
Heart failure patients visiting the outpatient clinic
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of understanding and signing informed consent
* A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
Exclusion Criteria
* Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
* Impaired renal function, defined as eGFR \< 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
* Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
* COPD Gold stage IV
* Congenital heart disease
* Pregnancy
* Coexistent condition with life expectancy of \<1 year
* Unlikely to appear at all scheduled follow-up visits
* Linguistic barrier
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ikazia Hospital, Rotterdam
OTHER
Franciscus Gasthuis & Vlietland (Hospital)
OTHER
OLVG
NETWORK
Free University Medical Center
OTHER
Noordwest Ziekenhuisgroep
OTHER
Erasmus Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Isabella Kardys
Prof. dr., MD PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Noordwest Ziekenhuisgroep
Alkmaar, North Holland, Netherlands
Amsterdam UMC
Amsterdam, North Holland, Netherlands
OLVG Ziekenhuis
Amsterdam, North Holland, Netherlands
Franciscus Gasthuis & Vlietland Ziekenhuis
Rotterdam, South Holland, Netherlands
Erasmus MC
Rotterdam, South Holland, Netherlands
Ikazia Ziekenhuis
Rotterdam, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mylene Loncq de Jong, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC-2022-0408
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.